Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Dec 8, 2009
Cambridge, MA, December 8, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M. Epizyme initially announced a $32M ro...
Oct 20, 2009
Cambridge, MA, October 20, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today that Dr. Hoyoung Huh, President and CEO of BiPar Sciences, Inc., was appointed Epizyme's Chairman of the Board of Directors. Epizyme recently ann...
Oct 7, 2009
Cambridge, MA, October 7, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC). Joining BCC as new investors are Amgen Ventures and As...
Sep 9, 2009
Cambridge, MA, Sepetember 9, 2009 - A paper underscoring the importance of protein methyltransferases (PMTs) in drug discovery is published in the September 2009 online issue of NATURE REVIEWS DRUG DISCOVERY. Scientists Dr. Robert A. Copeland and Dr. Victoria M. Richon from Epizyme, Inc. in their paper entitled "Protein methyl...
= add release to Briefcase